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INTRODUCTION
Methylene tetrahydrofolate reductase (MTHFR) is a cyto-
plasmic enzyme of which gene located on chromosome 1p36.3
in man. MTHFR catalyze the reduction of 5, 10-methylenete-
trahydrofolate to 5-methyltetrahydrofolate, the primary methyl
donor for the methylation of homocysteine to methionine.
Severe deficiency of MTHFR causes an increase in homocys-
teine levels and is associated with developmental delay, neu-
rological abnormalities and vascular complications (1-4).
The C677T MTHFR mutation involves the substitution of
an alanine residue for a valine, which results in a substantial
reduction in its thermolabile enzymatic activity. With two
copies of the TT variant, serum MTHFR activity is reduced
to 30% of that of wild-type (CC), whereas the serum activi-
ty of CT heterozygotes is 65% of the wild-type (5). There-
fore, the C677T MTHFR mutation is being viewed as a pos-
sible genetic contributor to hyper-homocysteinemia.
A direct relation between plasma homocysteine levels and
serum uric acid was observed in patients with atherosclero-
sis and in control subjects (6-10). These findings indicate
that the association between the two biochemical variables is
indeed strong in the presence of homozygosity for thermo-
labile MTHFR. This could imply a greater availability of 5,
10-methylenetetrahydrofolate, substrate of the MTHFR reac-
tion, for other metabolic uses, such as the de novo synthesis of
purines via 10-formyltetrahydrofolate, with consequent over-
production of uric acid.
Hyperuricemia is commonly associated with other known
risk factors for cardiovascular disease, such as obesity, hyperlipi-
demia, and hypertension, and in large epidemiological surveys,
such as the Framingham study, it has been related to the occur-
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The C677 Mutation in Methylene Tetrahydrofolate Reductase Gene:
Correlation with Uric Acid and Cardiovascular Risk Factors in Elderly
Korean men
The C677T mutation in the methylene tetrahydrofolate reductase (MTHFR) gene
results in elevated homocysteine levels and, presumably, in increased cardiovascu-
lar risk. Moreover, elevated homocysteine levels are reportedly associated with high
serum uric acid levels. We evaluated the MTHFR genotype and a panel of biochem-
ical, hematological variables, and lifestyle characteristics in 327 elderly Korean men
(age range 40-81 yr; mean, 51.87). This study shows that mutation of the MTHFR
gene may be a risk for hyperuricemia. The mean uric acid levels for the C/C, C/T
and T/T genotypes were 5.54, 5.91 and 6.33 mg/dL, respectively (p=0.000). The
T/T genotype was significantly more frequent in subjects with high uric acid levels
(p=0.003). Thus, this mutation of the MTHFR gene is implied by the study results to
be a risk factor of hyperuricemia in elderly Korean men. However, the relationship
between the MTHFR mutation and uric acid metabolism remains unclear. Therefore,
further studies are necessary to explain the associated between the MTHFR muta-
tion and elevated uric acid levels, and to examine potential relationships between
it and conventional cardiovascular risk factors.
Key Words : Methylenetetrahydrofolate Reductase (NADPH2); Uric Acid; Hyperuricemia; Cardiovas-
cular Diseases; Risk Factors
Received : 3 November 2003
Accepted : 15 December 2003210 Y.S. Hong, M.J. Lee, K.H. Kim, et al.
rence of myocardial infarction. Yet, these associations are not
fully understood.
Therefore, we studied a population of Korean elderly males,
in order to investigate the relationships between the C677T
MTHFR mutation and serum uric acid, and with other vari-
ables traditionally associated with cardiovascular risk.
MATERIALS AND METHODS
Study population
Three hundred and twenty-seven unrelated men, aged 40 yr
or more, were recruited into the study after obtaining informed
consent. All subjects underwent clinical examinations at Dong-
A University Hospital between September 2002 and June
2003. None of the subjects were diagnosed as having gout
or renal failure (>1.5 mg/dL of serum creatinine). The mean
age of the subjects was 51.9 yr (range, 40-81 yr). The per-
centages of subjects with hypertension (systolic blood pres-
sure, 160 mmHg or diastolic blood pressure, ≥95 mmHg),
diabetes mellitus or impaired glucose tolerance (hemoglobin
A1c (HbA1c), ≥6.5%), hypercholesterolemia (plasma total
cholesterol, ≥220 mg/dL), and hyperglyceridemia (triglyc-
erides, ≥150 mg/ dL) were 11.2%, 4.7%, 21.9% and 24.2%,
respectively. Body mass index (BMI) was computed as weight
(kg) divided by height (m2). Data on alcohol intake and smok-
ing habits were obtained by interview. The subjects were
asked to quantify their consumption of alcohol in terms of the
kind of alcoholic beverage usually drunk and the minimum
consumption per week. Alcohol intakes were then convert-
ed into grams of alcohol per day. The number of cigarettes
smoked per day was also noted.
Blood sample collection and DNA extraction
A venous blood sample was drawn from each of the partici-
pants. DNA was extracted, using a Wizard Genomic DNA
Purification Kit (Promega, Madison, U.S.A.), and stored at
-20℃ until analyzed. Serum was used for clinical chemistry
laboratory examinations at Dong-A University Hospital.
MTHFR genotyping
Polymerase chain reaction (PCR) was carried out using a
PCR thermal cycler (TP2000; Takara Biomedicals, Kyoto,
Japan). Thirty microliters of reaction mixture contained 200
ng of genomic DNA in 1× Expanded High Fidelity buffer
(Boehringer Mannheim, Amsterdam, The Netherland) with
1.5 mM MgCl2, 250  M dNTPs, 0.5  M primers, and 0.7
units of Expand High Fidelity PCR System Enzyme Mix
(Boehringer Mannheim). The sequences of the primers were
as follows: 5′ -TGAAGGAGGTGTCTGCGGGA-3′ and 5′ -
AGGACGGTGCGGTGAGAGTG-3′ (11). The conditions
for PCR included an initial denaturation at 94℃ for 3 min,
followed by 30 cycles of denaturation at 94℃ for 1 min,
annealing at 55℃ for 2 min, extension at 72℃ for 3 min,
and a final extension at 72℃ for 7 min. The amplified pro-
ducts were digested with HinfI (New England Biolabs, Bever-
ly, MA, U.S.A.) at 37℃ for 4 hr. The C-to-T transition cre-
ates a new HinfI site. Digested products were electrophoresed
in 3% agar gel.
Biochemical determinations
The following clinical chemistry variables were determined
in serum by standard enzymatic methods: total cholesterol,
high-density lipoprotein (HDL) cholesterol, triglycerides, glu-
cose, uric acid, creatinine, urea, total protein, alanine amino-
transferase, aspartate aminotransferase,  -glutamyltranspep-
tidase, and alkaline phosphatase. A whole blood cell count was
taken for each subjects.
Statistical analyses
For statistical purposes, all variables showing a non-Gaus-
sian distribution were logarithmically transformed. Analysis
of variance (ANOVA) and Scheff’ s F-test were used to com-
pare the means of subjects classified according to MTHFR
genotype. The odds ratio (OR) and 95% confidence interval
(95% CI) were calculated to estimate the relative risk of hype-
ruricemia associated with the MTHFR genotype. Study vari-
ables were correlated with uric acid levels, using Pearson’ s
correlation coefficient test or Spearman’ s correlation coeffi-
cient by rank test.
To allow for the independent contribution of MTHFR geno-
type and other variables to serum uric acid, multiple regres-
sion analysis were performed, including some of the variables
significantly associated with serum uric acid in univariate anal-
ysis. In the analysis, MTHFR genotypes were designated as
follows: C/C=0, C/T=1, T/T=2 (10). Other variables are pre-
sented as continuous form. Analyses were performed using
SPSS 10.1 (U.S.A.) and Epi-Info 2002 (WHO).
RESULTS
Distribution of MTHFR genotypes
The distribution of MTHFR genotypes was: C/C, 35.8%;
C/T, 49.5%; T/T, 14.7%. Alle frequencies were 60.5% for the
C allele and 39.5% for the T allele. These findings were con-
sistent with previous Korean reports (12, 13).
Physical and biochemical variables in subjects by
MTHFR genotype
The distribution of physical and biochemical variables, insubjects classified by MTHFR genotype, is shown in Table 1.
For all variables, except for uric acid and creatinine, no signif-
icant differences were found between the MTHFR genotype
subjects groups.
MTHFR genotype and uric acid level
The serum uric acid levels for each genotype are shown in
Table 2. The serum uric acid levels differed significantly in
subjects with different MTHFR genotypes (F=7.555; p=0.001).
Homozygotes for the MTHFR mutation had a significantly
higher mean uric acid level (6.33±0.97 mg/dL mean±SD)
than those without (5.54±1.26 mg/dL Scheffe’ s F-test, p=
0.005), whereas heterozygotes had an intermediate value (5.91
±1.18 mg/dL). Thus, a trend towards an increasing uric acid
level was observed as the number of T allele copies increased.
As shown in Table 2, subjects were classified into two groups
based on uric acid levels: a low uric acid group (<7.0 mg/dL)
and a high uric acid group (≥7.0 mg/dL). The value of 7.0
mg/dL represents the upper limit of the normal range of serum
uric acid in all males in our laboratory, and thus was chosen
as a cut-off value. The genotype frequencies differed signifi-
cantly between these two groups ( 2=9.44; df=2; p=0.009).
The T allele frequency was also significantly greater in the
high uric acid group than in the low uric acid group ( 2=
8.76; df=1; p=0.003).
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Variable Mean
MTHFR genotype
C/C (117) C/T (162) T/T (48)
p value
Age (yr) 51.87 51.43±8.73 51.72±8.78 53.5±9.22 0.373
BMI (kg/m
2) 24.22 23.92±2.65 24.38±3.23 24.39±3.03 0.535
Systolic blood pressure (mg/dL) 120.00 120.09±18.50 118.96±16.13 123.31±14.40 0.849
Diastolic blood pressure (mg/dL) 76.24 75.76±11.77 75.88±11.90 78.60±11.41 0.909
Total cholesterol (mg/dL) 197.98 198.79±35.55 197.22±28.14 198.63±27.79 0.905
HDL-cholesterol (mg/dL) 57.19 57.11±11.91 57.79±12.98 55.38±8.52 0.474
Log triglycerides (mg/dL) 2.08 2.09±0.29 2.06±0.25 2.14±0.16 0.083
Blood glucose (mg/dL) 99.57 102.10±35.15 99.35±31.45 94.13±11.71 0.320
Total protein (g/dL) 7.19 7.19±0.40 7.21±0.38 7.10±0.31 0.197
Creatinine (mg/dL) 0.98 0.95±0.20 0.97±0.13 1.04±0.13 0.007*
Blood urea nitrogen (mg/dL) 16.55 16.11±3.77 16.76±3.17 16.90±2.57 0.087
Uric acid (mg/dL) 5.84 5.54±1.26 5.91±1.18 6.33±0.97 0.001*
Hematocrit (%) 40.60 40.50±4.05 40.86±3.67 39.98±4.37 0.324
HbA1c (%) 4.96 4.98±0.94 5.13±1.12 4.93±0.97 0.532
Alkaline phosphatase (IU/L) 169.85 166.54±38.70 171.63±47.91 171.94±46.91 0.606
Alcohol (g/day) 19.41 19.36±21.81 19.95±34.87 17.73±20.43 0.896
Smoking (cigarettes/day) 8.36 8.73±10.95 7.94±12.74 8.88±9.73 0.816
*p<0.05. The values in different MTHFR genotypes (means±SD) were compared by analysis of variance (ANOVA). BMI, Body mass index; HDL,
high density lipoprotein.







Low uric acid level ( <7.0 mg/dL) 97 (40.4%) 113 (47.1%) 30 (12.5%) 0.36
High uric acid level (≥7.0 mg/dL) 20 (23.0%) 49 (56.3%) 18 (20.7%) 0.49
Odds ratio (95% CI) 1.0 2.10 (1.13-3.95) 3.33 (1.29-8.61)
*
2=9.44; df=2; p=0.009: genotype frequencies differed significantly in the two groups. 
� 2=8.76; df=1; p=0.003; T allele frequency was higher in the
high uric acid group than in the low uric acid group.
CI, Confidence interval.
Table 2. Odds ratios of hyperuricemia associated with MTHFR genotypes
*p<0.05.
St. ,  standardized  coefficient.




Systolic blood pressure (mmHg) -0.083 0.389
Diastolic blood pressure (mmHg) 0.240 0.016*
Log triglycerides (mg/dL) 0.121 0.025*
Blood glucose (mg/dL) 0.046 0.395
Total protein (g/dL) 0.035 0.507
Creatiinine (mg/dL) 0.188 0.000*
Blood urea nitrogen (mg/dL) 0.078 0.133
Hematocrit (%) 0.050 0.364
R 0.457 0.000
Table 3. Multiple regression analysis using serum uric acid as
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The calculated odds ratios and the 95% CIs for the C/T and
the T/T genotypes were 2.10 (1.13-3.95) and 3.33 (1.29-8.61),
versus the C/C genotype (Table 3). Both of these effects were
significant (p=0.01 and p=0.005), suggesting that the T allele
has a codominant effect on the risk of hyperuricemia.
Univariate regression analyses
Univariate analysis, serum uric acid is correlated with
MTHFR genotype (number of copies of T allele per subject),
BMI, diastolic blood pressure, triglycerides, blood glucose,
total protein, creatinine, blood urea nitrogen, and hematocrit.
No relationship was found between the uric acid level and
other factors (age, total cholesterol, HDL-cholesterol, total
protein, HbA1c (%), alkaline phosphatase, alcohol, and smok-
ing).
To exclude possible biases caused by the presence of subjects
with hypertension, diabetes mellitus or impaired glucose tol-
erance, hypercholesterolemia, or hyperglyceridemia, subjects
with each of these conditions were left out of the list in turn.
Leaving out subjects with any of these conditions did not ch-
ange the results as to MTHFR genotype. The correlation coef-
ficients between MTHFR genotype and uric acid level fluc-
tuated between 0.195 and 0.237, but pvalues remained below
0.001.
Multiple regression analyses
To assess the independent contribution of the variables to
serum uric acid levels, multiple regression analysis was per-
formed, which included all variables significantly associated
with serum uric acid by univariate analyses. As shown in Table
3, MTHFR, BMI, diastolic blood pressure, log-triglycerides,
and creatinine were found to be independently associated with
serum uric acid levels, whereas, systolic blood pressure, blood
glucose, total protein and hematocrit did not.
DISCUSSION
Frosst et al. proposed the C677T MTHFR mutation as a
candidate for cardiovascular disease risk (11). However, the
majority of studies and a recent meta-analysis of more than
6000 genotyped patients and controls have failed to confirm
this (14). We presumed that the C677T MTHFRmutation
could exert its atherogenic role at least partially by association
with other recognized risk factors.
Motti et al. found a relationship between the C677T MTHFR
mutation and serum uric acid (10). Their data shows that,
increases in homocysteine in subjects with the C677T MTHFR
mutation are paralleled by increases in serum uric acid levels.
However, their subjects were an inseparable mixture of gen-
ders and ages; though higher uric acid levels were found in
men (18).
In our study of Korean elderly men, a dose-dependent rela-
tionship was found between the number of copies of the T
allele of the MTHFR gene and serum uric acid concentration
(Table 1). Compared with the low uric acid group, the preva-
lence of the T/T genotype and the frequency of the T allele
were higher in the group with elevated uric acid levels. The
calculated odds ratio and 95% CI of hyperuricemia showed
an increased risk of the C/T and T/T genotypes, rather than
the C/C genotype (Table 2). Multivariate analysis also demon-
strated that the C677T MTHFR mutation is an independent
predictor of hyperuricemia (Table 3).
Serum uric acid is usually considered a marker of renal dys-
function, and a risk factor of renal disease progression. In addi-
tion, more recent studies suggest that elevated serum uric acid
predict cardiovascular disease and cerebrovascular accidents
(15-21). Although uric acid was thought to be an inert end-
product of purine metabolism, and without physiological sig-
nificance, except in gouty diathesis.
Possible mechanisms underlying these associations may be
presented. First, adenosine originating from S-adenosyl-homo-
cysteine, and preferentially incorporated into a precursor pool
for uric acid, would link the syntheses of homocysteine and uric
acid (9). Second, in subjects with the T/T genotype, renovas-
cular atherosclerosis or the complications of systemic vascular
disease may reduce the renal clearance of uric acid, resulting in
elevated serum uric acid (10). Therefore, the MTHFR muta-
tion may be a risk factor that is involved in multiple metabol-
ic pathways related to vascular diseases.
However, it remains a matter of debate as to whether uric
acid is an independent predictor of mortality in patients with
cardiovascular disease, or whether it represents only an indi-
rect marker of adverse outcome by reflecting the association
between uric acid and other cardiovascular risk factors
In this study, by comparing serum uric acid levels with the
C677T MTHFR mutation, and with other variables by uni-
variate analysis and multiple regression analysis. Five factors
were found to be associated with hyperuricemia: the C677T
MTHFR mutation, diastolic blood pressure, creatinine, trigly-
cerides, and BMI. Compared with these factors, itself, may
contribute less to hyperuricemia, because it showed a lower
standard partial regression coefficient to serum uric acid.
To prevent cardiovascular disorders in those who carry the
C677T MTHFR mutation, supplementation with folate,
vitamin B6 and vitamin B12 has been recommended (22),
because inter-individual variation in homocysteine levels are
related to other biological traits. The regulation of homocyteine
is an example of a nutritional/genetic interaction, in which
dietary habits (i.e. the intake of folic acid) play an important
role, in addition, to strategies aimed at lowering serum uric
acid levels, such as weight control and reducing the intake
of foods containing purines.
The present study shows that mutation of the MTHFR
gene may be a risk factor for hyperuricemia in the Korean
elderly population. In addition, the study identifies fourC677 Mutation of MTHFR and Uric Acid 213
other factors associated with hyperuricemia. Thus, we pro-
pose the probable need for a medical management strategy
for those who are homozygous for the C677T MTHFR
mutation, and the need for additional longitudinal study to
determine the mechanism and role of uric acid as a risk fac-
tor of cardiovascular disease.
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